Abstract: Low density lipoprotein cholesterol (LDL-C) has been demonstrated to be closely involved with Atherosclerotic cardiovascular disease (ASCVD). Clinical guidelines indicate that Statins serve as the first choice to lower LDL-C, there remains some patients can not be tolerable to statins, or even large doses of statins fail to achieve the optimal level of LDL-C. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors can significantly reduce serum LDL-C level with good tolerance and safety. Recently, PCSK9 inhibitors have been approved to be used clinically by FDA.

Key words: Key words：LDL-C, PCSK9, PCSK9 inhibitor, LDLR